Coinbase Lists BIO and RSC, Boosts Token Market
- Coinbase lists BIO and RSC, impacting token markets.
- BIO surged 19% after listing news.
- RSC’s price increased initially but lacked momentum.
Coinbase, led by CEO Brian Armstrong, announced the listing of Bio Protocol (BIO) and ResearchCoin (RSC) on July 29, 2025, drawing market attention and price movement.
This listing highlights Coinbase’s influence on market dynamics, causing significant price shifts for the tokens involved, underscoring their compliance with digital asset safeguards.
Coinbase’s recent listing of Bio Protocol (BIO) and ResearchCoin (RSC) has drawn substantial attention from investors. Both tokens were added to Coinbase’s asset roadmap, stirring notable price activity in the markets, as seen in previous roadmaps.
Prominent among decision-makers is Coinbase’s CEO, Brian Armstrong, addressing concerns over potential conflicts due to his involvement with ResearchHub. Armstrong assured transparency, explaining all listing decisions are independent of his influence or voting power.
The announcement led to significant changes in market behavior, with BIO witnessing a 19% surge upon its inclusion on Coinbase’s platform. Such volatility was anticipated, given similar past patterns with Coinbase roadmap announcements.
Financial impacts have been evident, though RSC’s initial 10% rise lacked sustained traction. No significant institutional investments or funding rounds have been publicly disclosed for these assets, according to current official data.
Expectations around these listings include potential ripple effects across the blockchain sector. However, lack of declared regulatory feedback from agencies like the SEC limits forecast precision.
Technological and financial prospects remain closely monitored, with analysts citing historical precedents from other Coinbase listings. Further price action or liquidity shifts could follow as trading activity rationalizes over time.
“All assets listed on Coinbase go through our Digital Asset Support Group (DASG) review. DASG conducts a review of all assets listed on Coinbase from legal, compliance, and cybersecurity perspectives; I am not a member of DASG, so I do not have voting power to decide which assets receive listing approval; My relationship with ResearchHub has been disclosed to the Coinbase Board, which is standard practice; I wrote a blog post on this topic in March 2022 and publicly committed not to sell RSC for at least four years—this commitment remains unchanged.” — Brian Armstrong, CEO, Coinbase
